| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5623248 | Alzheimer's & Dementia | 2013 | 8 Pages |
Abstract
We find support for our earlier proposal that (â)-phenserine did not fail, but the methods of development did fail, to provide conditions where efficacy could be tested. We propose that redevelopment under conditions aimed to correct methodological deficiencies common in AD drug developments will successfully test efficacy for (â)-phenserine and hopefully lead to a disease-modifying addition to the AD therapeutic armamentarium.
Keywords
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Robert E. Becker, Nigel H. Greig,